You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • THU0341 Cost Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naïve RA Adult Patients by Anti-Cyclic Citrullinated Peptide-Positive Subgroups

Citation Tools

Article menu
Download PDFPDF
Poster Presentations
Epidemiology, health services and outcome research
THU0341 Cost Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naïve RA Adult Patients by Anti-Cyclic Citrullinated Peptide-Positive Subgroups

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Alemao E, Schiff M, Johal S, et al
THU0341 Cost Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naïve RA Adult Patients by Anti-Cyclic Citrullinated Peptide-Positive Subgroups
Annals of the Rheumatic Diseases 2015;74:319.